v3.26.1
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Information
Significant segment expenses which are regularly reported to the CODM for purposes of making decisions regarding the allocation of resources are included within the table below and are reconciled to consolidated net loss (in thousands):
Three months ended June 30,Six months ended June 30,
2026202520262025
Total revenue$9,238 $11,489 $26,193 $21,378 
Less:
Seralutinib25,914 41,575 68,264 79,616 
Other segment items (1)
9,398 8,679 28,869 17,337 
     Interest income(268)(542)(622)(836)
     Interest expense2,705 2,744 5,460 5,490 
     Remeasurement of warrant liability(1,602)— (1,602)— 
     Remeasurement of derivative liability(4,113)— (4,113)— 
     Gain on debt extinguishment(43,846)— (43,846)— 
     Other income, net4,150 (2,694)3,547 (5,318)
Segment net gain (loss)$16,900 $(38,273)$(29,764)$(74,911)
(1) Other segment items include general and administrative expenses, which are provided to the CODM regularly, but are included within other segment items as they are not utilized as part of the decision making process as it relates to the allocation of resources. Further, R&D expenses for other terminated programs are also provided to the CODM. These costs include employee expenses, as well as allocations of consolidated overhead and stock compensation. Other segment items also include costs related to Respira (as defined in Note 13 below).